Home Featured Page 278

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

CB Therapeutics Closes on Oversubscribed Series A

Psychedelic Therapy for Borderline Personality Disorder?

Psychedelics Today’s 5th Birthday Party

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits...

Wesana Health Commences Trading on the CSE

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Psychedelic Research Bulletin: April 2021

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain;...

Cancer Patients’ Life Lessons Post-Psilocybin Treatment

PTSF58 – Liberty, The Power of Therapy, and Mushrooms in Maine

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

CB Therapeutics Closes on Oversubscribed Series A

Psychedelic Therapy for Borderline Personality Disorder?

Psychedelics Today’s 5th Birthday Party

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits...

Wesana Health Commences Trading on the CSE

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Psychedelic Research Bulletin: April 2021

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain;...

Cancer Patients’ Life Lessons Post-Psilocybin Treatment

PTSF58 – Liberty, The Power of Therapy, and Mushrooms in Maine

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY